LeapFinancial | $3,500,000 | (Dec 20, 2024)
TG0 | $5,619,170 | (Dec 20, 2024)
Mindgard | $8,000,000 | (Dec 20, 2024)
AOA Dx
United States
- Boulder, CO
- 13/10/2023
- Unknown
- $17,000,000
AOA Dx is developing the next frontier in early-stage cancer detection through its pioneering work in glycolipids and proprietary biomarker technology. Our revolutionary tumor marker ganglioside platform, GlycoLocate™, is paving the way for life-saving early cancer detection. In a first of its kind, AOA Dx has developed AKRIVIS GD™, an early-stage liquid biopsy test for ovarian cancer, that has proven excellent sensitivity and specificity in a recent study. We foresee novel tumor biomarker gangliosides as the future for diagnosis, prognosis, monitoring, and eventually targeted therapies across multiple cancers. AOA Dx was co-founded by three experts and passionate advocates of women’s health, who have worked together at two previous diagnostic startups, that both resulted in successful exits upon commercialization.
AOA Dx, a Y combinator and VC backed company, raised an oversubscribed Seed Round to accelerate development and clinical studies.
Awards & Accelerators:
1. Y Combinator
2. MassChallenge
3. Springboard Enterprises
4. MassMedic Ignite
5. Inc Magazine Top 100 Female Founders
6. Women's Health Innovation Summit Award
7. Massachusetts Life Sciences Center MassNextGen Award
8. The Wave Summit's Emerging Women Founder in Bio Award
9. The Eddies Award
www.aoadx.com
- Industry Biotechnology Research
- Website https://aoadx.com/
- LinkedIn https://www.linkedin.com/company/aoadx/about/
Related People
Oriana Papin-ZoghbiCo Founder
United States -
ND
Oriana Papin-Zoghbi is the CEO and co-founder of AOA Dx. She is a visionary leader in the field of women's health and diagnostics. Recently honored in Inc’s 2022 Top 100 Female Founders for her work in ovarian cancer diagnosis, Oriana brings a wealth of knowledge and expertise bringing disruptive diagnostics to market and changing the landscape of clinical practice. Oriana is passionate about entrepreneurship and problem solving and hopes to use these skills to revolutionize early cancer detection, particularly in cancers that disproportionately affect women.
Oriana has global experience creating and leading organizations resulting in successful strategic exits. Prior to AOA, she led teams at early-stage startups and large life sciences companies. Oriana has a track record of developing a highly productive culture and turning visions into reality. She has a proven technical record of creating market entry strategies and product launches in new markets, including launching nationwide HPV screening in East Africa and novel diagnostics in maternal fetal medicine, oncology and infectious diseases.
As CEO of AOA Dx, she has raised over $7M in Seed funding and $1M in non-dilutive grant funding. She has been accepted into numerous competitive accelerators including Y Combinator, MassChallenge, Springboard Enterprises and MassMedic Ignite. Her dedication and work have earned her numerous awards and recognition, including the Massachusetts Life Sciences Center MassNextGen Award, The Eddies People's Choice Award and The Wave Summit's Emerging Women Founder in Bio Award,
Oriana holds a degree from Boston University in Economics and International Relations, and she has experience both living and working in various geographies.
www.aoadx.com
Twitter: @orianazh
ŌURA | $200,000,000 | (Dec 20, 2024)
Buildpeer | $2,500,000 | (Dec 20, 2024)
Embeddable | $6,238,050 | (Dec 20, 2024)
Tenor | $5,400,000 | (Dec 20, 2024)
SOTELIX Endoscopy | $1,700,000 | (Dec 20, 2024)
Double(US) | $3,900,000 | (Dec 20, 2024)
Hauler Hero | $10,000,000 | (Dec 20, 2024)
TripSuite | $5,000,000 | (Dec 20, 2024)
Seekho | $8,000,000 | (Dec 19, 2024)